Cătălin Cezar Caratașu

Dr. Cătălin Cezar Caratașu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
ITIvona Maria Tudorancea
Ivona Maria Tudorancea
MCMitica Ciorpac
Mitica Ciorpac
Gabriela-Dumitrita StanciuGabriela-Dumitrita Stanciu
Gabriela-Dumitrita Stanciu
CCCătălin Cezar Caratașu
Cătălin Cezar Caratașu
ASAlina Săcărescu
Alina Săcărescu
BTBogdan Tamba
Bogdan Tamba
The endocannabinoid system (ECS) dynamically regulates many aspects of mammalian physiology. ECS has gained substantial interest since growing evidence suggests that it also plays a major role in several pathophysiological conditions due to its ability to modulate various underlying mechanisms. Furthermore, cannabinoids, as components of the cannabinoid system (CS), have proven beneficial effects such as anti-inflammatory, immunomodulatory, neuromodulatory, antioxidative, and cardioprotective effects. In this comprehensive review, we aimed to describe the complex interaction between CS and most common age-related diseases such as neuro-degenerative, oncological, skeletal, and cardiovascular disorders, together with the potential of various cannabinoids to ameliorate the progression of these disorders. Since chronic inflammation is postulated as the pillar of all the above-mentioned medical conditions, we also discuss in this paper the potential of CS to ameliorate aging-associated immune system dysregulation.

9 June 2023 in Medicina
Verified
Journal Article
Open access
PDF file
Magdalena CuciureanuMagdalena Cuciureanu
Magdalena Cuciureanu
CCCătălin Cezar Caratașu
Cătălin Cezar Caratașu
LGLevon Gabrielian
Levon Gabrielian
OFOtilia-Elena Frasinariu
Otilia-Elena Frasinariu
LCLaura Checherita
Laura Checherita
BTBogdan Tamba
Bogdan Tamba
Alarming statistics show that the number of people affected by excessive weight has surpassed 2 billion, representing approximately 30% of the world’s population. The aim of this review is to provide a comprehensive overview of one of the most serious public health problems, considering that obesity requires an integrative approach that takes into account its complex etiology, including genetic, environmental, and lifestyle factors. Only an understanding of the connections between the many contributors to obesity and the synergy between treatment interventions can ensure satisfactory outcomes in reducing obesity. Mechanisms such as oxidative stress, chronic inflammation, and dysbiosis play a crucial role in the pathogenesis of obesity and its associated complications. Compounding factors such as the deleterious effects of stress, the novel challenge posed by the obesogenic digital (food) environment, and the stigma associated with obesity should not be overlooked. Preclinical research in animal models has been instrumental in elucidating these mechanisms, and translation into clinical practice has provided promising therapeutic options, including epigenetic approaches, pharmacotherapy, and bariatric surgery. However, more studies are necessary to discover new compounds that target key metabolic pathways, innovative ways to deliver the drugs, the optimal combinations of lifestyle interventions with allopathic treatments, and, last but not least, emerging biological markers for effective monitoring. With each passing day, the obesity crisis tightens its grip, threatening not only individual lives but also burdening healthcare systems and societies at large. It is high time we took action as we confront the urgent imperative to address this escalating global health challenge head-on.

3 May 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Leontina Elena FilipiucLeontina Elena Filipiuc
Leontina Elena Filipiuc
RSRaluca Stefanescu
Raluca Stefanescu
CSCarmen Solcan
Carmen Solcan
MCMitica Ciorpac
Mitica Ciorpac
Andrei SzilagyiAndrei Szilagyi
Andrei Szilagyi
VBVeronica Bild
Veronica Bild
The conundrum of Cannabis sativa’s applications for therapeutical purposes is set apart by the hundreds of known and commercially available strains, the social, cultural and historical context, and the legalization of its use for medical purposes in various jurisdictions around the globe. In an era where targeted therapies are continuously being developed and have become the norm, it is imperative to conduct standardized, controlled studies on strains currently cultivated under Good Manufacturing Practices (GMP) certification, a standard that guarantees the quality requirements for modern medical and therapeutic use. Thus, the aim of our study is to evaluate the acute toxicity of a 15.6% THC: <1% CBD, EU-GMP certified, Cannabis sativa L. in rodents, following the OECD acute oral toxicity guidelines, and to provide an overview of its pharmacokinetic profile. Groups of healthy female Sprague-Dawley rats were treated orally with a stepwise incremental dose, each step using three animals. The absence or presence of plant-induced mortality in rats dosed at one step determined the next step. For the EU GMP-certified Cannabis sativa L. investigated, we determined an oral LD50 value of over 5000 mg/kg in rats and a human equivalent oral dose of ≈806.45 mg/kg. Additionally, no significant clinical signs of toxicity or gross pathological findings were observed. According to our data, the toxicology, safety and pharmacokinetic profile of the tested EU-GMP-certified Cannabis sativa L. support further investigations through efficacy and chronic toxicity studies in preparation for potential future clinical applications and especially for the treatment of chronic pain.

5 March 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AVAndrei Vicovan
Andrei Vicovan
DPDiana Cezarina Petrescu
Diana Cezarina Petrescu
ACAurelia Cretu
Aurelia Cretu
CGCristina Mihaela Ghiciuc
Cristina Mihaela Ghiciuc
DCDaniela Constantinescu
Daniela Constantinescu
CELINA SILVIA STAFIECELINA SILVIA STAFIE
CELINA SILVIA STAFIE
Neutrophils, known to be mobilized and activated in high amounts through Il-17 stimulation, are a key factor for clinical manifestation and imbalance of redox systems favoring a dominant oxidative state in both severe asthma and acute lung injury (f). The aim of this study was to evaluate in mice, the effect of Secukinumab (SECU) in a model of ovalbumin-induced asthma exacerbated with LPS administration to induce ALI, compared to dexamethasone (DEXA), already known for its benefit in both asthma and ALI. Results on cytokine levels for specific Th1, Th2 and Th17 revealed an interplay of immune responses. For Th1 effector cytokines in BALF, DEXA treatment increased TNF-α levels, but TNF-α was not modified by SECU; DEXA and SECU significantly decreased IFN-γ and IL-6 levels. For typical Th2 cytokines, DEXA significantly increased Il-4, Il-5 and Il-13 levels, while SECU significantly inhibited Il-5 levels. Both SECU and DEXA significantly decreased Il-17 levels. Cytokine level changes in lung tissue homogenate were partly similar to BALF cytokines. Conclusion: in addition to DEXA, SECU possesses the ability to modulate inflammatory cytokine release and to decrease Th17 responses in ALI overlapped on exacerbated asthma in mice.

11 July 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
AVAndrei Vicovan
Andrei Vicovan
DPDiana Cezarina Petrescu
Diana Cezarina Petrescu
DCDaniela Constantinescu
Daniela Constantinescu
EIElena Iftimi
Elena Iftimi
ICIrina Teodora Cernescu
Irina Teodora Cernescu
CGCristina Mihaela Ghiciuc
Cristina Mihaela Ghiciuc
This study investigates the combined treatment of secukinumab (SECU) and magnolol (MAGN) in a mouse model of LPS-induced ALI overlapped with allergic pulmonary inflammation, aiming to better understand the mechanism behind this pathology and to assess the therapeutic potential of this novel approach in addressing the severity of ALI. The combined treatment reveals intricate immunomodulatory effects. Both treatments inhibit IL-17 and promote M2 macrophage polarization, which enhances anti-inflammatory cytokine production such as IL-4, IL-5, IL-10, and IL-13, crucial for lung repair and inflammation resolution. However, the combination treatment exacerbates allergic responses and increases OVA-specific IgE, potentially worsening ALI outcomes. MAGN pretreatment alone demonstrates higher potency in reducing neutrophils and enhancing IFN-γ, suggesting its potential in mitigating severe asthma symptoms and modulating immune responses. The study highlights the need for careful consideration in therapeutic applications due to the combination treatment’s inability to reduce IL-6 and its potential to exacerbate allergic inflammation. Elevated IL-6 levels correlate with worsened oxygenation and increased mortality in ALI patients, underscoring its critical role in disease severity. These findings offer valuable insights for the advancement of precision medicine within the realm of respiratory illnesses, emphasizing the importance of tailored therapeutic strategies.

27 March 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
DSDragoș Viorel Scripcariu
Dragoș Viorel Scripcariu
CCCătălin Cezar Caratașu
Cătălin Cezar Caratașu
MCMitică Ciorpac
Mitică Ciorpac
TATeodora Alexa-Stratulat
Teodora Alexa-Stratulat
ASAndrei Szilagyi
Andrei Szilagyi
BTBogdan Ionel Tamba
Bogdan Ionel Tamba
Background: Radiation therapy, integral to pelvic tumor management, impacts over half of all cancer patients and may lead to anal sphincter dysfunction due to inflammatory responses and chronic fibrotic remodeling in irradiated tissues. To address this, a targeted animal model has been developed to investigate early post-radiotherapy anal toxicity and evaluates the efficacy of anti-fibrotic and anti-inflammatory agents, Pirfenidone and Meloxicam, as potential treatments against radiotherapy-induced sphincter dysfunction.Methods: Thirty male Sprague Dawley rats received a 30Gy dose via stereotactic body radiotherapy targeting the anal canal and sphincter. For 28 days, anal sphincter functionality was assessed using anorectal manometry, involving electrostimulation of the perianal area. Histological evaluations were conducted to qualitatively and quantitatively analyze morphological changes and measure sphincter thickness, providing insights into post-radiation structural integrity.Results: Irradiated animals exhibited signs of perianal inflammation, without severe complications such as strictures or perforations. Functional assessments showed altered sphincter contractility, with irradiated animals initially displaying increased contraction parameters, which subsequently declined to levels below baseline measurements. The groups treated with Pirfenidone, alone and in combination with Meloxicam exhibited significant improvements in sphincter contractility and showed a notable mitigation in external anal sphincter thickness, concomitant with reduction in collagen deposition and preservation of muscular tissue, compared with untreated irradiated animals.Conclusion: This study demonstrates that Pirfenidone, either as monotherapy or in combination with Meloxicam, mitigates radiation-induced fibrotic remodeling and preserves anal sphincter function. However, the combination therapy did not provide an additive benefit over Pirfenidone alone. These findings highlight Pirfenidone as a promising therapeutic strategy for managing post-radiotherapy sphincter dysfunction. Further research is needed to elucidate the underlying molecular mechanisms and optimize antifibrotic and myoprotective interventions for clinical application in cancer survivors.